Osteoporosis in the Women's Health Initiative: Another Treatment Gap?.

MedStar author(s):
Citation: American Journal of Medicine. , 2017 Mar 30American Journal of Medicine. 130(8):937-948, 2017 AugPMID: 28366425Institution: MedStar Washington Hospital CenterDepartment: Medicine/EndocrinologyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Bone Density Conservation Agents/tu [Therapeutic Use] | *Calcium/tu [Therapeutic Use] | *Osteoporosis/dt [Drug Therapy] | *Osteoporotic Fractures/pc [Prevention & Control] | *Patient Acceptance of Health Care/sn [Statistics & Numerical Data] | *Vitamin D/tu [Therapeutic Use] | Aged | Educational Status | Female | Forecasting | Humans | Logistic Models | Longitudinal Studies | Middle Aged | Multicenter Studies as Topic | Osteoporosis/co [Complications] | Osteoporosis/ep [Epidemiology] | Osteoporotic Fractures/ep [Epidemiology] | Social Class | United States/ep [Epidemiology] | Women's Health/sn [Statistics & Numerical Data]Year: 2017Local holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - presentISSN:
  • 0002-9343
Name of journal: The American journal of medicineAbstract: BACKGROUND: Osteoporotic fractures are associated with high morbidity, mortality, and cost.CONCLUSION: Despite well-established treatment guidelines in postmenopausal women with osteoporosis and/or history of fractures, pharmacotherapy use was suboptimal in this study. Initiation of osteoporosis treatment after fragility fracture may represent an opportunity to improve later outcomes in these high-risk women. Specific attention needs to be paid to increasing treatment among women with fragility fractures, obesity, current tobacco use, history of arthritis or of black race/ethnicity.Copyright (c) 2017. Published by Elsevier Inc.METHODS: We performed a post hoc analysis of the Women's Health Initiative (WHI) clinical trials (CT) data to assess osteoporosis treatment and identify participant characteristics associated with utilization of osteoporosis medication(s) after new diagnoses of osteoporosis and/or fracture. Information from visits prior to and immediately subsequent to the first fracture event or osteoporosis diagnosis were evaluated for medication use. A full logistic regression model was used to identify factors predictive of osteoporosis medication use after a fracture and/or a diagnosis of osteoporosis.RESULTS: The median length of follow-up from enrollment to the last WHI clinic visit for the study cohort was 13.9 years. Among the 13,990 women who reported new diagnoses of osteoporosis and/or fracture between enrollment and their final WHI visit, and also had medication data available, 21.6% reported taking an osteoporosis medication other than estrogen. Higher daily calcium intake, diagnosis of osteoporosis alone or both osteoporosis and fracture (compared to diagnosis of fracture alone), Asian or Pacific Islander race/ethnicity (compared to white/Caucasian), higher income, and hormone therapy use (past or present) were associated with significantly higher likelihood of osteoporosis pharmacotherapy. Women with black/African-American race/ethnicity (compared to white/Caucasian), BMI > 30 (compared to BMI of 18.5-24.9), current tobacco use (compared to past use or lifetime nonusers), and history of arthritis were less likely to use osteoporosis treatment.All authors: Beyth RJ, Cauley JA, Garvan C, Johnson KC, LaMonte MJ, Li W, Limacher M, Manini T, Sarto GE, Sattari M, Sullivan SD, Wactawski-Wende JFiscal year: FY2017Digital Object Identifier: Date added to catalog: 2017-05-06
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 28366425 Available 28366425

Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - present

BACKGROUND: Osteoporotic fractures are associated with high morbidity, mortality, and cost.

CONCLUSION: Despite well-established treatment guidelines in postmenopausal women with osteoporosis and/or history of fractures, pharmacotherapy use was suboptimal in this study. Initiation of osteoporosis treatment after fragility fracture may represent an opportunity to improve later outcomes in these high-risk women. Specific attention needs to be paid to increasing treatment among women with fragility fractures, obesity, current tobacco use, history of arthritis or of black race/ethnicity.

Copyright (c) 2017. Published by Elsevier Inc.

METHODS: We performed a post hoc analysis of the Women's Health Initiative (WHI) clinical trials (CT) data to assess osteoporosis treatment and identify participant characteristics associated with utilization of osteoporosis medication(s) after new diagnoses of osteoporosis and/or fracture. Information from visits prior to and immediately subsequent to the first fracture event or osteoporosis diagnosis were evaluated for medication use. A full logistic regression model was used to identify factors predictive of osteoporosis medication use after a fracture and/or a diagnosis of osteoporosis.

RESULTS: The median length of follow-up from enrollment to the last WHI clinic visit for the study cohort was 13.9 years. Among the 13,990 women who reported new diagnoses of osteoporosis and/or fracture between enrollment and their final WHI visit, and also had medication data available, 21.6% reported taking an osteoporosis medication other than estrogen. Higher daily calcium intake, diagnosis of osteoporosis alone or both osteoporosis and fracture (compared to diagnosis of fracture alone), Asian or Pacific Islander race/ethnicity (compared to white/Caucasian), higher income, and hormone therapy use (past or present) were associated with significantly higher likelihood of osteoporosis pharmacotherapy. Women with black/African-American race/ethnicity (compared to white/Caucasian), BMI > 30 (compared to BMI of 18.5-24.9), current tobacco use (compared to past use or lifetime nonusers), and history of arthritis were less likely to use osteoporosis treatment.

English

Powered by Koha